Screening of alternative drugs to the tumor suppressor miR-375 in esophageal squamous cell carcinoma using the connectivity map

Oncology (Switzerland)

Volumn 87, Issue 6, 2014, Pages 351-363

  Isozaki, Yuka ^a   Hoshino, Isamu ^a   Akutsu, Yasunori ^a   Hanari, Naoyuki ^a   Mori, Mikito ^a   Nishimori, Takanori ^a   Murakami, Kentaro ^a   Akanuma, Naoki ^a   Toyozumi, Takeshi ^a   Takahashi, Masahiko ^a   Suito, Hiroshi ^a   Takeshita, Nobuyoshi ^a   Maruyama, Tetsuro ^a   Suzuki, Akane ^a   Nakayama, Toshinori ^a   Matsubara, Hisahiro ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antitumor effect; Catechin; Connectivity map; Esophageal squamous cell carcinoma; Metformin; miR 375; Pathway analysis; Rosiglitazone

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; BENZOCAINE; CHENODEOXYCHOLIC ACID; EPIGALLOCATECHIN GALLATE; FOSFOSAL; METFORMIN; MICRORNA 375; NIZATIDINE; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTINEOPLASTIC AGENT; BETAZOLE; CATECHIN; CYTOTOXIN; MICRORNA; MIRN375 MICRORNA, HUMAN; ORGANOPHOSPHATE; PRIMER DNA; PROLINE; STACHYDRINE; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER SCREENING; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONNECTOME; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IC50; NICK END LABELING; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; ESOPHAGEAL NEOPLASMS; GENETIC TRANSFECTION; GENETICS; METABOLISM; PROTEIN MICROARRAY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOCAINE; BETAZOLE; CARCINOMA, SQUAMOUS CELL; CATECHIN; CELL LINE, TUMOR; CHENODEOXYCHOLIC ACID; CYTOTOXINS; DNA PRIMERS; ESOPHAGEAL NEOPLASMS; HUMANS; IN SITU NICK-END LABELING; METFORMIN; MICRORNAS; NIZATIDINE; ORGANOPHOSPHATES; PROLINE; PROTEIN ARRAY ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; THIAZOLIDINEDIONES; TRANSCRIPTOME; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84922393618     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000365592     Document Type: Article

References (32)

1. Enzinger PC, Mayer RJ: Esophageal cancer. N Engl J Med 2003; 349: 2241-2252.
2. Filipowicz W, Bhattacharyya SN, Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9: 102-114.
3. Hoshino I, Matsubara H: MicroRNAs in cancer diagnosis and therapy: from bench to bedside. Surg Today 2013; 43: 467-478.
4. Hoshino I, Matsubara H: Recent advances in histone deacetylase targeted cancer therapy. Surg Today 2010; 40: 809-815.
5. Isozaki Y, Hoshino I, Nohata N, Kinoshita T, Akutsu Y, Hanari N, Mori M, Yoneyama Y, Akanuma N, Takeshita N, Maruyama T, Seki N, Nishino N, Yoshida M, Matsubara H: Identification of novel molecular targets regulated by tumor suppressive miR-375 induced by histone acetylation in esophageal squamous cell carcinoma. Int J Oncol 2012; 41: 985-994.
6. Gavrilov K, Saltzman WM: Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med 2012; 85: 187-200.
7. Gheeya J, Johansson P, Chen QR, Dexheimer T, Metaferia B, Song YK, Wei JS, He J, Pommier Y, Khan J: Expression profiling identifies epoxy anthraquinone derivative as a DNA topoisomerase inhibitor. Cancer Lett 2010; 293: 124-131.
8. Zhang XZ, Yin AH, Lin DJ, Zhu XY, Ding Q, Wang CH, Chen YX: Analyzing gene expression profile in K562 cells exposed to sodium valproate using microarray combined with the connectivity map database. J Biomed Biotechnol 2012; 2012: 654291.
9. Hoshino I, Matsubara H, Akutsu Y, Nishimori T, Yoneyama Y, Murakami K, Komatsu A, Sakata H, Matsushita K, Ochiai T: Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells. Oncol Rep 2007; 18: 585-592.
10. Hoshino I, Matsubara H, Hanari N, Mori M, Nishimori T, Yoneyama Y, Akutsu Y, Sakata H, Matsushita K, Seki N, Ochiai T: Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells. Clin Cancer Res 2005; 11: 7945-7952.
11. Murakami K, Matsubara H, Hoshino I, Akutsu Y, Miyazawa Y, Matsushita K, Sakata H, Nishimori T, Usui A, Kano M, Nishino N, Yoshida M: CHAP31 induces apoptosis only via the intrinsic pathway in human esophageal cancer cells. Oncology 2010; 78: 62-74.
12. Kano M, Yamada S, Hoshino I, Murakami K, Akutsu Y, Sakata H, Nishimori T, Usui A, Miyazawa Y, Kamada T, Tsujii H, Matsubara H: Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-Acid-containing peptide 31 in human esophageal squamous cell carcinoma. Anticancer Res 2009; 29: 4433-4438.
13. Lamb J: The connectivity map: a new tool for biomedical research. Nat Rev Cancer 2007; 7: 54-60.
14. Vilar E, Mukherjee B, Kuick R, Raskin L, Misek DE, Taylor JM, Giordano TJ, Hanash SM, Fearon ER, Rennert G, Gruber SB: Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. Clin Cancer Res 2009; 15: 2829-2839.
15. De Preter K, De Brouwer S, Van Maerken T, Pattyn F, Schramm A, Eggert A, Vandesompele J, Speleman F: Metamining of neuroblastoma and neuroblast gene expression profiles reveals candidate therapeutic compounds. Clin Cancer Res 2009; 15: 3690-3696.
16. Reka AK, Kuick R, Kurapati H, Standiford TJ, Omenn GS, Keshamouni VG: Identifying inhibitors of epithelialmesenchymal transition by connectivity map-based systems approach. J Thorac Oncol 2011; 6: 1784-1792.
17. Chen D, Wan SB, Yang H, Yuan J, Chan TH, Dou QP: EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment. Adv Clin Chem 2011; 53: 155-177.
18. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W, Yang CS: Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003; 63: 7563-7570.
19. Pan MH, Lin CC, Lin JK, Chen WJ: Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-Activated protein kinase cascade signaling. J Agric Food Chem 2007; 55: 5030-5037.
20. Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928.
21. Ashihara E, Kawata E, Nakagawa Y, Shimazaski C, Kuroda J, Taniguchi K, Uchiyama H, Tanaka R, Yokota A, Takeuchi M, Kamitsuji Y, Inaba T, Taniwaki M, Kimura S, Maekawa T: Beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model. Clin Cancer Res 2009; 15: 2731-2738.
22. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N: Metformin inhibits mammalian target of rapamycindependent translation initiation in breast cancer cells. Cancer Res 2007; 67: 10804-10812.
23. Engelman JA, Cantley LC: Chemoprevention meets glucose control. Cancer Prev Res (Phila) 2010; 3: 1049-1052.
24. Komiya M, Fujii G, Takahashi M, Iigo M, Mutoh M: Prevention and intervention trials for colorectal cancer. Jpn J Clin Oncol 2013; 43: 685-694.
25. Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, Koide T, Tokoro C, Abe Y, Inamori M, Nakagama H, Nakajima A: Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 2010; 3: 1077-1083.
26. Malaviya A, Sylvester PW: Mechanisms mediating the effects of gamma-tocotrienol when used in combination with PPARgamma agonists or antagonists on MCF-7 and MDA-MB-231 breast cancer cells. Int J Breast Cancer 2013; 2013: 101705.
27. Cheung KF, Zhao J, Hao Y, Li X, Lowe AW, Cheng AS, Sung JJ, Yu J: CITED2 is a novel direct effector of peroxisome proliferator-Activated receptor gamma in suppressing hepatocellular carcinoma cell growth. Cancer 2013; 119: 1217-1226.
28. Cerbone A, Toaldo C, Minelli R, Ciamporcero E, Pizzimenti S, Pettazzoni P, Roma G, Dianzani MU, Ullio C, Ferretti C, Dianzani C, Barrera G: Rosiglitazone and AS601245 decrease cell adhesion and migration through modulation of specific gene expression in human colon cancer cells. PLoS One 2012; 7:e40149.
29. Zha X, Wang F, Wang Y, He S, Jing Y, Wu X, Zhang H: Lactate dehydrogenase B is critical for hyperactive mTORmediated tumorigenesis. Cancer Res 2011; 71: 13-18.
30. Lee SG, Su ZZ, Emdad L, Sarkar D, Franke TF, Fisher PB: Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling. Oncogene 2008; 27: 1114-1121.
31. van Everdink WJ, Baranova A, Lummen C, Tyazhelova T, Looman MW, Ivanov D, Verlind E, Pestova A, Faber H, van der Veen AY, Yankovsky N, Vellenga E, Buys CH: RFP2, c13ORF1, and FAM10a4 are the most likely tumor suppressor gene candidates for B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 2003; 146: 48-57.
32. Zhang X, Wu Q, Gan L, Yu GZ, Wang R, Wang ZS, Wang JJ, Wang X: Reduced group IVA phospholipase A2 expression is associated with unfavorable outcome for patients with gastric cancer. Med Oncol 2013; 30: 454.